Articles On Amplia Therapeutics (ASX:ATX)
Title | Source | Codes | Date |
---|---|---|---|
Top 10 at 10: Which ASX stocks are getting the stamp of approval today?
Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | ATX | 1 year ago |
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m... |
Stockhead | ATX | 1 year ago |
Here’s why NeuroScientific (ASX:NSB) share price is climbing today
Highlights The HREC gave a green signal to NeuroScientific for conducting an early-phase clinical trial of its lead drug candidate. The trial will evaluate the biomarkers in human blood samples that provide proof for the working mechan... |
Kalkine Media | ATX | 1 year ago |
Closing Bell: Small caps retreat, Credit Suisse adds weight to lithium lunge
Emerging companies fall 0.7% ASX200 0.8% lower Superior Resources (ASX:SPQ) jumps on copper system find, Galileo up … heaps in May The Emerging Companies (XEC) index is lower on Thursday, weighed down by broad losses as Credit Suisse a... |
Stockhead | ATX | 1 year ago |
Amplia Therapeutics (ASX:ATX) shows efficacy in model of lung fibrosis
Amplia Therapeutics (ATX) releases new data showing its AMP945 treatment returns similar efficacy results to the current standard of care for idiopathic pulmonary fibrosis New data from Amplia’s preclinical studies demonstrated AMP945 show... |
themarketherald.com.au | ATX | 1 year ago |
ASX Health Stocks: Alterity is set to launch Phase 2 clinical trial on Multiple System Atrophy
Alterity to launch Phase 2 clinical trial Pro Medicus signs multimillion dollar deal Amplia demonstrates efficacy for lead asset, AMP945 Alterity to launch Phase 2 clinical trial Neurodegenerative diseases specialist, Alterity Therapeutic... |
Stockhead | ATX | 1 year ago |
Market Highlights and 5 ASX Small Caps to watch on Thursday
ASX 200 will open lower after a fall on Wall Street overnight OPEC+ will meet to discuss higher output The ASX gets a new CEO Aussie shares are set to fall this morning after Wall Street finished lower following a volatile session overnig... |
Stockhead | ATX | 1 year ago |
Amplia Therapeutics’ (ASX:ATX) gets HREC nod for pancreatic cancer trial
Highlights Amplia Therapeutics has received second HREC clearance for Phase 2 clinical trial of AMP945 The approval will allow the company to accelerate recruitment into the trial and focus on its execution phase The trial is designed... |
Kalkine Media | ATX | 1 year ago |
Market Highlights and 5 ASX Small Caps to watch on Friday
ASX is set to end the week lower San Fran Fed President Mary Daly signals that a 75bp hike may be off the cards Bitcoin’s crash this week is the biggest since May 2021 ASX to fall, Bitcoin crashes Aussie shares are set to open lower agai... |
Stockhead | ATX | 1 year ago |
Amplia Therapeutics (ASX:ATX) receives final ethics clearance for Phase 2 trial
Amplia Therapeutics (ATX) receives the final ethics clearance to conduct a phase two clinical trial The company gained approval from a second Human Research Ethics Committee (HREC) for the clinical trial of its Focal Adhesion Kinase (FAK)... |
themarketherald.com.au | ATX | 1 year ago |
Amplia Therapeutics’ (ASX:ATX) pancreatic cancer study receives green light from US FDA
Amplia Therapeutics’ (ATX) pre-investigational new drug (IND) interaction with the US Food and Drug Administration is given the green light The company sought the FDA’s feedback on the design of its planned clinical study of its AMP945 tre... |
themarketherald.com.au | ATX | 1 year ago |
Check Up: Money managers are still bullish on Healthcare; here’s what they said
The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week Dr Anthony Faucci, America’s top infectious disea... |
Stockhead | ATX | 1 year ago |
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly
The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot... |
Stockhead | ATX | 1 year ago |
Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?
Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve... |
Stockhead | ATX | 1 year ago |
Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month
Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal... |
Stockhead | ATX | 2 years ago |
Closing Bell: Screwball takeovers and lack of war lifts ASX, small caps stunned
So basically, this is how I read it. Because of two really screwball takeover ideas involving the A2 Milk Co and AGL Energy — two of the more screwball companies floating about on the benchmark index — the S&P/ASX200 is higher on Monda... |
Stockhead | ATX | 2 years ago |
Amplia Therapeutics’ (ASX:ATX) AMP945 improves survival in human pancreatic cancer model
Amplia Therapeutics’ (ATX) pancreatic cancer drug, AMP945 has been shown to improve the effectiveness of Gemcitabine and Abraxane in a model of human pancreatic cancer The study conducted at the Garvan Institute established pancreatic tumo... |
themarketherald.com.au | ATX | 2 years ago |
ASX Health Stocks: Amplia Therapeutics gains momentum on pancreatic cancer drug
At the time of writing, the ASX 200 Health Index (XHJ) is up by another 3.3%, while the benchmark ASX 200 has risen by 0.5%. Cancer and fibrosis focused biotech Amplia Therapeutics (ASX:ATX) said its AMP945 drug improves effectiveness of cu... |
Stockhead | ATX | 2 years ago |
Amplia says new report 'paves the way' for its phase 2 trial
Amplia (ASX:ATX) has reported the publication of a key paper in the peer-reviewed journal Science Advances that shows pre-treatment with a FAK inhibitor improves the effectiveness of chemotherapy in a preclinical model of pancreatic... |
BiotechDispatch | ATX | 2 years ago |
Market Highlights and 5 ASX Small Caps to watch on Thursday
Wall Street mixed on subdued Fed minutes Investors breathed a sigh of relief overnight after the Fed minutes were less hawkish than many expected. The minutes showed that rates will be raised in March along with a reduction in the size of t... |
Stockhead | ATX | 2 years ago |
Amplia Therapeutics' AMP945 shown to improve effectiveness of gemcitabine/Abraxane® in human pancreatic cancer
Researchers at the Garvan Institute have shown that the addition of AMP945 pre-treatment to a gemcitabine/Abraxane® chemotherapy regimen increased survival by 33%. |
Proactive Investors | ATX | 2 years ago |
Check Up: Johnson & Johnson manoeuvre causes a stir, as CSL pulls Healthcare higher on the ASX
The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby... |
Stockhead | ATX | 2 years ago |
Amplia Therapeutics to showcase clinical data at major cancer conference
“The AACR is one of the most recognised international forums for cancer research and we are delighted that the results of our phase one trial have been selected for presentation at this prestigious meeting,” says CEO. |
Proactive Investors | ATX | 2 years ago |
Amplia Therapeutics readies for phase two clinical trials and "watershed year" for AMP945
|
Proactive Investors | ATX | 2 years ago |
Amplia Therapeutics well placed for pipeline progression in the new year
“While 2021 was a challenging year for everyone, I am extremely proud of what our team at Amplia has been able to achieve. In the last quarter of 2021, we put in place all the elements to make 2022 a watershed year for the company," says CE... |
Proactive Investors | ATX | 2 years ago |
Amplia Therapeutics readies for phase 2 pancreatic cancer trial after lead drug manufactured
Amplia Therapeutics (ASX: ATX) is a step closer to phase 2 clinical trials in pancreatic cancer and lung fibrosis after completing a manufacturing run of its lead focal adhesion kinase (FAK) inhibitor drug AMP945. The company’s contractor h... |
SmallCaps | ATX | 2 years ago |
Amplia Therapeutics (ASX:ATX) set for AMP945 drug trials
Amplia Therapeutics (ATX) completes manufacture of its clinical-stage drug candidate ahead of planned trials A two-kilogram batch of the company’s AMP945 will be used in toxicology studies and phase two clinical trials in pancreatic cancer... |
themarketherald.com.au | ATX | 2 years ago |
Amplia Therapeutics completes AMP945 manufacturing run ahead of phase two clinical trials
The batch was produced on time and within budget and represents a big step up from the 1-kilogram batch that’s been manufactured under GMP conditions previously. |
Proactive Investors | ATX | 2 years ago |
Check Up: As Omicron rages, rapid antigen testing specialist Atomo surges nearly 50pc
At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform... |
Stockhead | ATX | 2 years ago |
Amplia Therapeutics looks to build on clinical momentum in 2022
“Our priorities for 2022 are clear – our goal will be to build on the solid foundations of the last 12 months and maintain this momentum as we move towards two phase-two trials in the new year,” says CEO. |
Proactive Investors | ATX | 2 years ago |
Check Up: Anteotech riding high with $1.9m refund, and Avecho inks supply agreement for CBD arthritis treatment
It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %... |
Stockhead | ATX | 2 years ago |
Healthcare has been a hot sector. Here are the top ASX biotech stocks in 2021
The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19 ravaged the world. Nasdaq-listed BioNTech, which... |
Stockhead | ATX | 2 years ago |
Amplia Therapeutics Ltd to pursue anti-cancer drug development thanks to fully underwritten entitlement offer
The cash injection will fund the first stage of phase two clinical trials for AMP945, as well as manufacturing and further pre-clinical studies and additional working capital. |
Proactive Investors | ATX | 2 years ago |
Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables
It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont... |
Stockhead | ATX | 2 years ago |
Amplia Therapeutics receives $2.1m grant to fast-track second cancer drug AMP886
Pharmaceutical company Amplia Therapeutics (ASX: ATX) has been granted a $2.1 million funding facility to accelerate work on its second focal adhesion kinase (FAK) inhibitor drug AMP886 for treating cancers and fibrotic disease. The company... |
SmallCaps | ATX | 2 years ago |
Amplia Therapeutics (ASX:ATX) granted $2.1 million R&D cash flow loan
Amplia Therapeutics (ATX) has been granted a $2.1 million Research and Development (R&D) cash flow loan The $2.1 million will be awarded in two tranches: $1.3m in December this year and $0.8 million in the quarter ending March 31, 2022... |
themarketherald.com.au | ATX | 2 years ago |
Amplia Therapeutics drug candidates make further strides toward cancer and fibrotic diseases treatment
Amplia has designed a Phase 2 clinical trial of AMP945 in pancreatic cancer patients and plans to initiate patient recruitment at Australian sites in the first quarter of calendar 2022. |
Proactive Investors | ATX | 2 years ago |
Check Up: Sustainable Nutrition riding high and Singular Health branches out from… health
It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M... |
Stockhead | ATX | 2 years ago |
Amplia Therapeutics' Phase 1 clinical trial shows AMP945 is safe and well tolerated at all doses tested
The company is optimistic about the results of its Phase 1 clinical trial with results supporting further development of AMP945 as a treatment for cancer and fibrosis. |
Proactive Investors | ATX | 2 years ago |
Amplia Therapeutics confirms anti-cancer drug AMP945 can inhibit focal adhesion kinase in healthy volunteers
Australian pharmaceutical company Amplia Therapeutics (ASX: ATX) has received new data from a recent Phase 1 clinical trial which demonstrates the ability of lead drug AMP945 to inhibit focal adhesion kinase (FAK) in healthy human volunteer... |
SmallCaps | ATX | 2 years ago |
Amplia Therapeutics details summary results from its phase 1 clinical trial of AMP945
|
Proactive Investors | ATX | 2 years ago |
ASX Health Stocks: Amplia eyes human trials for pancreatic cancer drug
Amplia targets human trials for pancreatic cancer drug Noxopharm subsidiary enters licence agreement with Hudson Insitiute of Medical Research $7.2 million placement and $2 million SPP launched by Pharmaxis to support next phase of clinica... |
Stockhead | ATX | 2 years ago |
10 at 10: These ASX stocks have struck the jackpot this morning
Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov... |
Stockhead | ATX | 2 years ago |
Amplia Therapeutics' new data reveals inhibition of Focal Adhesion Kinase in humans
The data will be used to further refine the doses of AMP945 to be used in a Phase 2 clinical trial in patients with pancreatic cancer and will provide guidance for the Phase 2 trial in pulmonary fibrosis planned for the second half of 2022. |
Proactive Investors | ATX | 2 years ago |
Amplia Therapeutics talks A$12.4 million capital raise to support phase 2 clinical trial
|
Proactive Investors | ATX | 2 years ago |
Amplia Therapeutics capital raise to fund phase two trial
The capital raise consists of a placement to institutional and sophisticated investors to raise $5.4 million and a one-for-four fully underwritten pro-rata non-renounceable entitlement offer to raise $7 million. |
BiotechDispatch | ATX | 2 years ago |
Amplia Therapeutics seeking A$12.4 million to progress pancreatic cancer clinical trial
Proceeds from the placement and entitlement offer will be used to fund the first stage of a Phase 2 clinical trial for AMP945, manufacturing and further pre-clinical studies. |
Proactive Investors | ATX | 2 years ago |
Closing Bell: ASX closes out the week 1.8pc higher
The ASX had a positive finish to the week taking its weekly return to 1.8%. Today the ASX 200 closed at 7,457 points, 0.39% higher than yeterday. Tech was heavily sold off, shedding 1.64% but almost all other sectors were in the green with... |
Stockhead | ATX | 2 years ago |
Closing Bell: $20.3bn was raised on ASX in October, up 166pc year-on-year
The ASX rose 0.48% today to reach its highest point in the week. While energy lost 2% most other sectors were in the green with tech and financials gaining over 1%. Today’s gains came despite the Federal Reserve unveiling a tapering of stim... |
Stockhead | ATX | 2 years ago |
Amplia Therapeutics (ASX:ATX) enters trading halt
Pharmaceutical company Amplia Therapeutics (ATX) enters into a trading halt as it plans an upcoming capital raise It is not known how much the company is aiming to raise or where the funds will be spent Under the halt, company shares will... |
themarketherald.com.au | ATX | 2 years ago |